Abstract 1457P
Background
Oligometastatic (OMD) non-small cell lung cancer (NSCLC) is a distinct but heterogeneous entity. Current guidelines recommend locally ablative therapy if technically feasible. Still, evidence is lacking to guide the choice of optimal multimodal treatment approaches and their impact on clinical endpoints.
Methods
Electronic medical records and clinical databases (years 2004 – 2022) from two major German comprehensive cancer centers were searched for cases with OMD NSCLC and treatment patterns. Prespecified OMD criteria included presence of ≤5 metastases in ≤2 organ systems, excluding primary tumor and mediastinal lymph nodes. Endpoints of this retrospective analysis were overall survival (OS), disease-free survival (DFS, first-line therapy until recurrence) and time-to-treatment failure (TTF).
Results
A total of 207 patients with OMD NSCLC were identified (46.9% female; median age 60.8; median follow-up 32 months; T1-2 vs. T3-4 51%/49%, N0-1 vs. N2-3 48%/52%, M1a 10.7%, metastases in one organ system 89.7% vs. multiple 10.3%). A dedicated OMD treatment strategy was explicitly specified in 164 patients (79.2%). Locally ablative therapy was applied to all tumor sites in 140 patients (67.6%), including radiotherapy (85%) and/or surgery (73.6%). Median OS of the full analysis cohort was 27.7 months, with 27.2% OS at 5 years. Median OS in patients receiving locally ablative therapy to all NSCLC sites amounted to 33.4 months (5y rate 35.7%) with a median DFS of 10.6 months (11.2% at 5y). First-line therapy included systemic therapy in 167 patients (80.7%), which was associated with doubling of DFS (median 12.2 vs. 6.0 months, p<0.001), and a trend towards improved OS. First-line chemoimmunotherapy was only approved in 2018/2019, thus limiting follow-up in this subgroup. Nevertheless, DFS (HR 0.5, p=0.025, 2y rate 46% vs. 15%) and TTF (HR 0.45, p<0.001) were greatly improved with first-line chemoimmunotherapy vs. chemotherapy.
Conclusions
Patients with OMD NSCLC benefit from multimodality approaches integrating systemic therapy and local ablation of all cancer sites. Although true freedom from recurrence is rare, extended OS can be achieved in a substantial fraction of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Wiesweg: Financial Interests, Personal, Invited Speaker: Amgen, Roche, Takeda, GSK, AstraZeneca; Financial Interests, Personal, Advisory Board: GSK, Novartis, Pfizer, Roche, Janssen, Daiichi Sankyo; Financial Interests, Institutional, Local PI: Takeda; Financial Interests, Institutional, Funding: Bristol Myers Squibb. T. Plönes: Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Invited Speaker: BMS, Roche, AstraZeneca. M. Metzenmacher: Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol Myers Squibb, MSD, Novartis, Novocure, Pfizer, Roche, Takeda. W.E.E. Eberhardt: Financial Interests, Personal, Invited Speaker: AstraZeneca, Roche, Bristol Myers Squibb, MSD, Boehringer Ingelheim, Lilly, Amgen, Takeda, Pfizer, Novartis, Roche, Sanofi, AbbVie; Financial Interests, Personal, Advisory Board: AstraZeneca, Roche, Bristol Myers Squibb, MSD, Bayer, Lilly, Boehringer Ingelheim, Takeda, Pfizer, MSD, Novartis, Sanofi, AbbVie, Amgen, Janssen; Financial Interests, Institutional, Research Funding: AstraZeneca, Lilly, Bristol Myers Squibb; Non-Financial Interests, Personal and Institutional, Steering Committee Member: IASLC Staging Committee, M-track. A. Stenzinger: Financial Interests, Personal, Advisory Board: Aignostics, AstraZeneca, Janssen, Bayer, Seattle Genetics, Pfizer, MSD, Eli Lilly, Illumina, Thermo Fisher, Amgen; Financial Interests, Institutional, Advisory Board: BMS, Takeda, Novartis; Financial Interests, Personal, Invited Speaker: Roche, Incyte; Financial Interests, Institutional, Research Grant: Bayer, Chugai, BMS, Incyte. F. Weykamp: Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD. M. Thomas: Financial Interests, Personal, Advisory Board: AstraZeneca, BeiGene, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Chugai, Daiichi Sankyo, GSK, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda; Financial Interests, Institutional, Research Funding: AstraZeneca, Bristol Myers Squibb, Merck, Roche, Takeda. M.H.H. Schuler: Financial Interests, Personal, Invited Speaker: Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, Roche; Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Janssen, Merck Serono, Novartis, Roche, Sanofi, Takeda; Financial Interests, Institutional, Research Grant: AstraZeneca, Bristol Myers Squibb. P. Christopoulos: Financial Interests, Personal, Advisory Board: AstraZeneca, Boehringer Ingelheim, Chugai, Pfizer, Novartis, MSD, Takeda, Roche, Daiichi Sankyo; Financial Interests, Personal, Writing Engagement: Gilead; Financial Interests, Personal, Invited Speaker: Thermo Fisher; Financial Interests, Institutional, Funding: AstraZeneca, Boehringer Ingelheim, Amgen, Novartis, Roche; Financial Interests, Personal, Funding: Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
1411P - Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)
Presenter: Grace Dy
Session: Poster session 20
1412P - SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors
Presenter: Alessandra Curioni-Fontecedro
Session: Poster session 20
1414P - Impact of co-mutations on the prognosis of targeted therapy in EGFR-mutant advanced NSCLC: A result of real-world study
Presenter: Sisi Pan
Session: Poster session 20
1416P - Recurrence of infusion-related reaction (IRRs) associated to avimantamab
Presenter: Maria Virginia Sanchez Becerra
Session: Poster session 20
1417P - Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2019: An observational study from the French national claims database
Presenter: Christos Chouaid
Session: Poster session 20
1418P - Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study
Presenter: Rupesh Kotecha
Session: Poster session 20
1419P - TACSTD2 (Trop-2) constitutes a promising antibody-drug conjugate target for patients with non-small cell lung cancer brain metastases
Presenter: Sara Hijazo-Pechero
Session: Poster session 20
1420P - Real-life management of octogenarians with NSCLC in a French nationwide cohort
Presenter: Romain Corre
Session: Poster session 20
1421P - AI-powered intracranial tumor response predicts systemic progression with high concordance in endpoint evaluation in the phase III CROWN study
Presenter: Shao-Lun Lu
Session: Poster session 20